CRISPR Therapeutics
MA - Boston
Biotechnology2 H-1B visas (FY2023)Focus: CRISPR-Cas9 therapy
CRISPR Therapeutics is a life sciences company focused on CRISPR-Cas9 therapy.
Gene Therapy
Open Jobs
9
Pipeline & Clinical Trials
Non Interventional
Hematologic MalignancyClinical Trials (1)
NCT06208878A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
N/ACTX120
Multiple MyelomaClinical Trials (1)
NCT04244656A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1CTX130
T Cell LymphomaClinical Trials (1)
NCT04502446A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
Phase 1VCTX210A unit
Diabetes MellitusClinical Trials (1)
NCT05210530An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
Phase 1CTX112
SLE (Systemic Lupus)Clinical Trials (1)
NCT06925542A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1CTX130
Renal Cell CarcinomaClinical Trials (1)
NCT04438083A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
Phase 1CTX112
B-cell LymphomaClinical Trials (1)
NCT05643742A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT05795595A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Phase 1/2CTX110
B-cell MalignancyClinical Trials (1)
NCT04035434A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2CTX131
T Cell LymphomaClinical Trials (1)
NCT06492304A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Phase 1/2VCTX211
Diabetes MellitusClinical Trials (1)
NCT05565248An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
Phase 1/2CTX001
Beta-ThalassemiaCTX001
Sickle Cell DiseaseCTX001
Beta-ThalassemiaCTX001
Beta-ThalassemiaCTX001
Sickle Cell DiseaseOpen Jobs (9)
Non-Clinical Medical Writer (Contract)
South Boston, MA
5d ago
$150 - $170/hr
Senior Clinical Scientist
South Boston, MA
1w ago
$140K - $160K/yr
Manufacturing Associate, LNP
Framingham, MA
Manufacturing4w ago
$35/hr
Senior Scientist, LNP MSAT
South Boston, MA
Research & Development1mo ago
$137K - $150K/yr
Director, Clinical Development CVD
South Boston, MA
Clinical Operations1mo ago
$190K - $220K/yr
Manager, Infusion Support Operations
South Boston, MA
Research & Development2mo ago
$118K - $130K/yr
Associate Director, Global Regulatory Lead
South Boston, MA
Regulatory Affairs2mo ago
$170K - $195K/yr
Senior Manager, Supply Chain
South Boston, MA
Supply Chain3mo ago
$130K - $150K/yr
Executive Director, External Manufacturing & Supply Chain
South Boston, MA
Manufacturing3mo ago
$260K - $290K/yr
Interview Prep Quick Facts
Portfolio: 11 clinical trials
Top TAs: Oncology, Immunology, Metabolic Diseases
H-1B (2023): 2 approvals
Open Roles: 9 active jobs
Therapeutic Area Focus
Marketed
Pipeline
Hiring Trend
Stable
9
Open Roles
+2
Added
-3
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub